1. Home
  2. Live Updates
  3. Iopharmaceutical

Live Breaking News & Updates on Iopharmaceutical

Stay informed with the latest breaking news from Iopharmaceutical on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Iopharmaceutical and stay connected to the pulse of your community

China's CAR T market comes of age

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

Nanjing , Jiangsu , China , Chinese , Wuxi-apptec-co , Pharmaceuticals-inc , Juno-therapeutics-inc , Legend-biotech-corp , Johnson , Juventas-cell-therapy-ltd , Nanjing-legend-biotech-corp

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

The increasing trend in strategic partnerships between innovator companies, and the US FDA approval for Rezdiffra has led to a boost in the development of medications for MASH.

Sweden , China , Chinese , Eli-lilly-zepbound , Rezdiffra-resmetirom , Madrigal-rezdiffra , Zealand-pharma , Bristol-myers-squibb-pegbelfermin , Novo-nordisk-ozempic , Alison-labya , Ribocure-pharmaceuticals , Global-partnership-deal-value

A look at drug development in Alzheimer's disease

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

Howard-fillit , Auguste-deter , Alzheimer-drug-discovery-foundation , Biogen-inc , National-academies , Drug-discovery-foundation , Biologics , Iopharmaceutical , Iotechnology , Rug , Ma , Da

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Exchange-commission , Twitter , Head-of-communications , Linkedin , Ocugen-inc , Private-securities-litigation-reform-act , Nasdaq-ocgn , Cugen , Iopharmaceutical , Iotech , Arnings

PRISM MarketView Highlights Work of Emerging Companies on

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day...

Neurocrine-biosciences , Cancer-prevention-pharmaceuticals-inc , Rare-disease-day , Priority-review , Biologics-license-application , Prescription-drug-user-fee-act , Prevention-pharmaceuticals , Duchenne-muscular-dystrophy , Regenerative-medicine-advanced-therapy , Diazoxide-choline , Prism-marketview

GCANRx Announces Completion of Preclinical Study for

BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company...

Jerusalem , Israel-general- , Israel , Hebrew-university , Yerushalayim , Boston , Massachusetts , United-states , Adi-aran , Aitan-zacharin , Intel , Google

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

University-of-texas , Texas , United-states , Bellicum-go , Katy-rezvani , Philip-jones , Cancer-center , Drug-administration , Research-strategy , Bellicum-pharmaceuticals-inc , Anderson-cancer , Bellicum-pharmaceuticals

Ocugen to Host Clinical Showcase in New York City

Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial...

New-york , United-states , Times-square , Lejla-vajzovic , Arun-upadhyay , Neena-haider , Shankar-musunuri , Harvard-medical-school , Head-of-communications , Duke-university-school-of-medicine , University-of-miami , Ocugen-inc

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

Erin-duffy , Gary-schoolnik , Sexual-health-test , Drug-administration , Antibiotic-resistant-bacteria-biopharmaceutical , Visby-medical , Chief-medical-officer , Antibiotic , Iagnostic , Onorrhea , Ntimicrobial-resistance

Rapidly distinguish protein from non-protein particles

Halo Labs introduces fluorescence membrane microscopy (FMM)

Application-note , Halo-labs , Biologic , Roteins , Echnology , Iopharmaceutical , Mm ,